GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

terevalefim   Click here for help

GtoPdb Ligand ID: 11997

Synonyms: ANG-3777 | ANG3777 | Refanalin
Compound class: Synthetic organic
Comment: Terevalefim (ANG-3777) is a clinical stage small molecule hepatocyte growth factor (HGF) mimetic. HGF as a pleiotropic factor with roles in organ regeneration [2-3,5]. Like HGF, terevalefim activates the HGF/c-MET pathway, to promote tissue and organ repair and function. Terevalefim was developed as a first-in-class therapeutic to target acute organ injury.

terevalefim is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 1
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 56.92
Molecular weight 176.04
XLogP 2.08
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES c1csc(c1)/C=C/c1[nH]ncc1
Isomeric SMILES c1csc(c1)/C=C/c1ccn[nH]1
InChI InChI=1S/C9H8N2S/c1-2-9(12-7-1)4-3-8-5-6-10-11-8/h1-7H,(H,10,11)/b4-3+
InChI Key FOHWAQGURRYJFK-ONEGZZNKSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Terevalefim (ANG-3777) has advanced to clinical investigation for potential to combat acute kidney injury. Based on ANG-3777-mediated activity in animal models of lung injury, it was evaluated for potential to combat acute lung damage in patients with severe COVID-19 related pneumonia who were at high risk for acute respiratory distress syndrome (ARDS), in a phase 2 trial (ALI-201; NCT04459676). The primary or secondary efficacy endpoints of the study were not met.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04459676 Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia Phase 2 Interventional Angion Biomedica Corp Terevalefim failed to demonstrate clinical efficacy in this study.
NCT02771509 Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass Phase 2 Interventional Angion Biomedica Corp
NCT02474667 Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney Phase 3 Interventional Angion Biomedica Corp 4